The Alzheimer's Disease Neuroimaging Initiative

Overview

Journal Neuroimaging Clin N Am

Specialties Neurology
Radiology

Date 2006 Jan 31

PMID 16443497

Citations 476

Authors

Susanne G Mueller

Michael W Weiner

Leon J Thal

Ronald C Petersen

Clifford Jack

William Jagust

John Q Trojanowski

Arthur W Toga

Laurel Beckett

Affiliations

Soon will be listed here.

Abstract

With increasing life expectancy in developed countries, the incidence of Alzheimer's disease (AD) and its socioeconomic impact are growing. Increasing knowledge of the mechanisms of AD facilitates the development of treatment strategies aimed at slowing down or preventing neuronal death. AD treatment trials using clinical outcome measures require long observation times and large patient samples. There is increasing evidence that neuroimaging and cerebrospinal fluid and blood biomarkers may provide information that may reduce sample sizes and observation periods. The Alzheimer's Disease Neuroimaging Initiative will help identify clinical, neuroimaging, and biomarker outcome measures that provide the highest power for measurement of longitudinal changes and for prediction of transitions.

Citing Articles

Brain functional connectivity analysis of fMRI-based Alzheimer's disease data.

Alarjani M, Almarri B Front Med (Lausanne). 2025; 12:1540297.

PMID: 40046917 PMC: 11880024. DOI: 10.3389/fmed.2025.1540297.

Reliability of structural brain change in cognitively healthy adult samples.

Vidal-Pineiro D, Sorensen O, Stromstad M, Amlien I, Anderson M, Baare W bioRxiv. 2025; .

PMID: 40027710 PMC: 11870432. DOI: 10.1101/2024.06.03.592804.

Reevaluating the Role of Education in Cognitive Decline and Brain Aging: Insights from Large-Scale Longitudinal Cohorts across 33 Countries.

Fjell A, Rogeberg O, Sorensen O, Amlien I, Bartres-Faz D, Brandmaier A Res Sq. 2025; .

PMID: 39989967 PMC: 11844660. DOI: 10.21203/rs.3.rs-5938408/v1.

Learning-based inference of longitudinal image changes: Applications in embryo development, wound healing, and aging brain.

Kim H, Karaman B, Zhao Q, Wang A, Sabuncu M Proc Natl Acad Sci U S A. 2025; 122(8):e2411492122.

PMID: 39977323 PMC: 11873959. DOI: 10.1073/pnas.2411492122.

Distinctive associations between plasma p-tau181 levels and hippocampal subfield volume across the Alzheimer's disease continuum.

Rich A, Oh H bioRxiv. 2025; .

PMID: 39975208 PMC: 11838288. DOI: 10.1101/2025.01.27.635113.

References

Mattson M . Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders. Neuromolecular Med. 2003; 3(2):65-94. DOI: 10.1385/NMM:3:2:65. View

DeKosky S . Pathology and pathways of Alzheimer's disease with an update on new developments in treatment. J Am Geriatr Soc. 2003; 51(5 Suppl Dementia):S314-20. DOI: 10.1046/j.1532-5415.5157.x. View

DeKosky S, Marek K . Looking backward to move forward: early detection of neurodegenerative disorders. Science. 2003; 302(5646):830-4. DOI: 10.1126/science.1090349. View

Bertram L, Tanzi R . The current status of Alzheimer's disease genetics: what do we tell the patients?. Pharmacol Res. 2004; 50(4):385-96. DOI: 10.1016/j.phrs.2003.11.018. View

Petersen R . Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004; 256(3):183-94. DOI: 10.1111/j.1365-2796.2004.01388.x. View

Blennow K . CSF biomarkers for mild cognitive impairment. J Intern Med. 2004; 256(3):224-34. DOI: 10.1111/j.1365-2796.2004.01368.x. View

Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund L . Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004; 256(3):240-6. DOI: 10.1111/j.1365-2796.2004.01380.x. View

DAVIS P, Gearing M, Gray L, Mirra S, Morris J, Edland S . The CERAD experience, Part VIII: Neuroimaging-neuropathology correlates of temporal lobe changes in Alzheimer's disease. Neurology. 1995; 45(1):178-9. DOI: 10.1212/wnl.45.1.178. View

Mielke R, Schroder R, Fink G, Kessler J, Herholz K, Heiss W . Regional cerebral glucose metabolism and postmortem pathology in Alzheimer's disease. Acta Neuropathol. 1996; 91(2):174-9. DOI: 10.1007/s004010050410. View

10.

Irizarry M . Biomarkers of Alzheimer disease in plasma. NeuroRx. 2005; 1(2):226-34. PMC: 534932. DOI: 10.1602/neurorx.1.2.226. View

11.

Mayeux R, Sano M . Treatment of Alzheimer's disease. N Engl J Med. 1999; 341(22):1670-9. DOI: 10.1056/NEJM199911253412207. View

12.

Irizarry M, Hyman B . Alzheimer disease therapeutics. J Neuropathol Exp Neurol. 2001; 60(10):923-8. DOI: 10.1093/jnen/60.10.923. View

13.

Mudher A, Lovestone S . Alzheimer's disease-do tauists and baptists finally shake hands?. Trends Neurosci. 2002; 25(1):22-6. DOI: 10.1016/s0166-2236(00)02031-2. View

14.

Pratico D, Clark C, Liun F, Rokach J, Trojanowski J . Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol. 2002; 59(6):972-6. DOI: 10.1001/archneur.59.6.972. View

15.

Hsu Y, Schuff N, Du A, Mark K, Zhu X, Hardin D . Comparison of automated and manual MRI volumetry of hippocampus in normal aging and dementia. J Magn Reson Imaging. 2002; 16(3):305-10. PMC: 1851676. DOI: 10.1002/jmri.10163. View

16.

Soto C . Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci. 2003; 4(1):49-60. DOI: 10.1038/nrn1007. View

17.

Taylor J, Hardy J, Fischbeck K . Toxic proteins in neurodegenerative disease. Science. 2002; 296(5575):1991-5. DOI: 10.1126/science.1067122. View